Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: Systematic review and network meta-analysis reveals the need for long term comparator trials

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 649-667

  Bodalia, Pritesh N ^a,b   Grosso, Anthony M ^a,c   Sofat, Reecha ^a   Macallister, Raymond J ^a   Smeeth, Liam ^d   Dhillon, Soraya ^e   Casas, Juan Pablo ^a,d   Wonderling, David ^f   Hingorani, Aroon D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Anticonvulsants therapeutic use; Comparative study; Epilepsy drug therapy; Meta analysis; Review; Treatment outcome

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ARTICLE; COMPARATIVE EFFECTIVENESS; COMPLEX PARTIAL SEIZURE; DRUG EFFICACY; DRUG TOLERABILITY; FOCAL EPILEPSY; GRAND MAL EPILEPSY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SIMPLE PARTIAL SEIZURE; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; VISUAL DISORDER;

ANTICONVULSANTS/THERAPEUTIC USE; COMPARATIVE STUDY; EPILEPSY/DRUG THERAPY; META-ANALYSIS; REVIEW; TREATMENT OUTCOME;

ANTICONVULSANTS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; EPILEPSIES, PARTIAL; HUMANS; RESEARCH DESIGN; TIME FACTORS;

EID: 84886908929     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12083     Document Type: Article

References (102)

1. Blume WT. Glossary of descriptive terminology for ictal semiology: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 1212-1218.
2. World Health Organization. Epilepsy. Fact Sheet number 999. 2009.
3. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996; 37: S1-S3.
4. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, Moshe SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-1077.
5. Cockerell OC, Sander JWAS, Hart YM, Shorvon SD, Johnson AL. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995; 346: 140-144.
6. Devinsky O. Patients with refractory seizures. N Engl J Med 1999; 340: 1565-1570.
7. Guidelines for clinical evaluation of antiepileptic drugs. Epilepsia 1989; 30: 400-408.
8. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JPA. Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest 2010; 40: 172-182.
9. National Institute for Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary care and secondary care. Clinical Guideline 137. 2012. Accessed 18-1-2012.
10. The mad world of epilepsy drugs. Drug Ther Bull 2009; 47: 49.
11. Institute of Medicine. Roundtable on evidence-based medicine. Learning what works best: the nation's need for evidence on comparative effectiveness in health care. 2008. 22-4-2010.
12. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press, 2009.
13. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009; 151: 203-205.
14. US Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research: Report to the President and the Congress. 2009.
15. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-2324.
16. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
17. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-3124.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896-1900.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
22. Higgins JPT. Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2008; 37: 1158-1160.
23. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224-233.
24. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
25. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055.
26. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Chichester: John Wiley & Sons, 2002.
27. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: John Wiley & Sons, 2004.
28. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001; 10: 277-303.
29. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
30. Lunn DJ, Thomas A, Best N, Spiegelhalter DJ. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325-337.
31. Lee PM. Bayesian Statistics: An Introduction, 4th edn. West Sussex, UK: Wiley, 2012.
32. Sackett DL, Strauss SE, Richardson WS, Rosenberg W, Haynes RB, eds. Evidence Based Medicine: How to Practice and Teach EBM. Edinburgh: Harcourt, 2000.
33. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998; 7: 434-455.
34. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol 2002; 64: 583-639.
35. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011.
36. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114-1117.
37. Sivenius J, Kalviainen R, Ylinen A, Riekkinen PJ. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32: 539-542.
38. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35: 795-801.
39. Yamauchi T, Kaneko S, Yagi K, Sase S. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci 2006; 60: 507-515.
40. Ben-Menachem E, Biton V, Jatuzis D, Abous D, Rudd D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-1317.
41. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, Sullivan T (on behalf of the SP755 Study Group). Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-453.
42. Loiseau P, Yuen AW, Duche B, Menager T, Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990; 7: 136-145.
43. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, Lineberry CG. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2284-2291.
44. Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, Pellock JM, Valakas AM, Womble G, Risner M. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35: 113-121.
45. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65: 1737-1743.
46. Naritoku DK, Warnock CR, Messenheimer JA, Borgohain R, Evers S, Guekht AB, Karlov VA, Lee BL, Rios Pohl L. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007; 69: 1610-1618.
47. Cereghino JJ, Biton V, Bou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
48. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-1186.
49. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-87.
50. Ben ME, Falter U. Efficacy and tolerability of levetiracetam 3000mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-1283.
51. Boon P, Chauvel P, Pohlmann EB, Otoul C, Wroe S. Dose-response effect of levetiracetam 1000 and 2000mg/day in partial epilepsy. Epilepsy Res 2002; 48: 77-89.
52. Tsai JJ, Yen DJ, Hsih MS, Chen SS, Hiersemenzel R, Edrich P, Lai CW. Efficacy and safety of levetiracetam (up to 2000mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47: 72-81.
53. Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskly L, Lu Z, Sykes DM. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009; 50: 406-414.
54. Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 2008; 12: 305-310.
55. Xiao Z, Li JM, Wang XF, Xiao F, Xi ZQ, Ly Y, Sun HB. Efficacy and safety of levetiracetam (3, 000mg/day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Eur Neurol 2009; 61: 233-239.
56. Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, Moore A, Flesch G, Kramer L, D'Souza J. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597-1607.
57. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631-1637.
58. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose response study in adults with partial seizures. Epilepsia 2004; 45: 20-27.
59. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64: 475-480.
60. Lee BI, Yi S, Hong SB, Kim MK, Lee SA, Lee SK, Shin DJ, Kim JM, Song HK, Heo K, Lowe W, Leon T. Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 2009; 50: 464-474.
61. Uthman BM, Rowan AJ, Ahmann PA, Leppik IE, Schachter SC, Sommerville KW, Shu V. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998; 55: 56-62.
62. Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res 1998; 30: 31-40.
63. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, Dam M, Reife R, Pledger G, Karim R. Double-blind, placebo-controlled trial of topiramate (600mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996; 37: 763-768.
64. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L, Pledger G, Karim R. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539-543.
65. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46: 1684-1690.
66. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1, 000-mg daily dosages. Topiramate YE Study Group. Neurology 1996; 46: 1678-1683.
67. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, Karim R. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996; 25: 217-224.
68. Yen DJ, Yu HY, Guo YC, Chen C, Yiu CH, Su MS. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000; 41: 1162-1166.
69. French JA, Mosier M, Walker S, Sommerville K, Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996; 46: 54-61.
70. Bruni J, Guberman A, Vachon L, Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure 2000; 9: 224-232.
71. Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, Egli M, Bauer G, Stenzel E, Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73.
72. Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774-1779.
73. Brodie MJ. Zonisamide clinical trials: European experience. Seizure 2004; 13: (Suppl. 1): S66-S70.
74. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, III, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004; 45: 610-617.
75. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31-41.
76. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res 1999; 34: 199-205.
77. Lindberger M, Alenius M, Frisen L, Johannessen SI, Larsson S, Malmgren K, Torason T. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in refractory epilepsy add-on treatment. Epilepsia 2000; 41: 1289-1295.
78. Baulac M, Leon T, O'Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset epilepsy. Epil Res 2010; 91: 10-19.
79. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-880.
80. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-1174.
81. Shorvon SD. The choice of drugs and approach to drug treatments in partial epilepsy. In: The Treatment of Epilepsy, 2nd edn. eds Shorvon SD, Perucca E, Fish D, Dodson E. Oxford: Blackwell Science Ltd, 2004; 317-333.
82. Otoul C, Arrigo C, Rijckevorsel KV, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005; 28: 72-78.
83. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010; 51: 7-26.
84. Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011; 52: 219-233.
85. Devinsky O, Cramer J. Safety and efficacy of standard and new antiepileptic drugs. Neurology 2000; 55: S5-10.
86. Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol 2004; 43: 1929-1939.
87. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472.
88. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534-2544.
89. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopex-Olivo MA, Ghogoma ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181: 787-796.
90. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J 2008; 29: 1086-1092.
91. Mills E, Perri D, Cooper C, Nachega JB, Wu P, Tleyjeh I, Phillips P. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob 2009; 8: 23.
92. Huynh T, Perron S, O'Loughlin J, Joseph L, Labracque M, Tu JV, Theroux P. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: Bayesian hierarchical meta-analyses of randomized controlled trials and observational studies. Circulation 2009; 119: 3101-3109.
93. Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003; 7(1).
94. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products in the Treatment of Epileptic Disorders [Draft]. CHMP/EWP/566/98 Rev. 2. 2009. accessed 22-4-2010.
95. Ioannidis JPA. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009; 181: 488-493.
96. Salanti G, Kavvoura FK, Ioannidis JPA. Exploring the geometry of treatment networks. Ann Intern Med 2008; 148: 544-553.
97. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-443.
98. Morrison A, Moulton K, Clark M, Polisena J, Fiander M, Mierzwinski-Urban M, Mensinkai S, Clifford T, Hutton B. English-Language Restriction When Conducting Systematic Review-Based Meta-Analyses: Systematic Review of Published Studies. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009.
99. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 2003; 7(41).
100. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WJ, Fischer JH, Bourgeois B, Wilner A, Faught RE, Sachdeo RC, Beydoun A, Glauser TA. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-1260.
101. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PEM, Tudur-Smith C, Vanoli A, Williamson PR. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000-1015.
102. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PEM, Tudur-Smith C, Vanoli A, Williamson PR. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.